Auto-Injectable Diazepam Formulation for Rapid Treatment of Uncontrolled Seizures
用于快速治疗失控癫痫发作的自动注射地西泮制剂
基本信息
- 批准号:9440793
- 负责人:
- 金额:$ 79.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-30 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdvanced DevelopmentAmendmentAnimalsAppearanceBiological AssayBiological AvailabilityCaregiversChemistryClinicalClinical ResearchClinical TrialsContractsCrystallizationCutaneousCyclic GMPDataDevelopmentDevicesDiazepamDoseDrug KineticsEffectivenessEmergency treatmentEpilepsyExhibitsFDA approvedFormulationFutureGelHome environmentHumanInjectableInjection of therapeutic agentIntravenousLeadLifeManufactured SuppliesMeasurementMethodologyMethodsMiniature SwineModelingNational Institute of Neurological Disorders and StrokeNeedlesNeuraxisParticulate MatterPatientsPersonsPharmaceutical PreparationsPharmacologic SubstancePharmacologyPharmacology StudyPhasePhase I Clinical TrialsRattusResearchResearch DesignRiskRouteSafetySeizuresSubcutaneous InjectionsSyringesSystemTechnologyTestingTherapeuticTimeToxicologyUpdateVial deviceabsorptionanalytical methodbasecommercializationcomparativedesignexperienceimprovedin vitro Assayin vivo Modelinnovationinterestintradermal injectionliquid chromatography mass spectrometrymanufacturing facilitynervous system disordernovelpreferenceprogramsrectalresearch clinical testingsocialstandard of caresubcutaneoususability
项目摘要
The program outlined in this Fast Track application has been designed to accelerate the development and
commercialization of the DiazePen™ for the treatment of uncontrolled seizures in persons with epilepsy. The
envisioned product would replace the current standard of care, diazepam rectal gel (DiaStat®), with a novel
formulation for rapid delivery via subcutaneous injection. For this effort, Xeris will use its proprietary formulation
platform (XeriSol™), which has already demonstrated feasibility of a very-low volume, stable diazepam with
pharmacokinetics similar to DiaStat®. Successful completion of the aims will advance development of the
DiazePen™ through the formulation optimization and nonclinical phase, IND application and manufacture of
clinical supplies for a future Phase 1 clinical trial that will be sponsored by Xeris Pharmaceuticals. This research
is directly relevant to the NINDS which is explicitly interested in the development of innovative therapeutics for
neurological disorders, including therapeutics (drugs, biologics, and/or devices) for treatment of neurological
disorders, and technologies/methodologies to deliver therapeutics to the central nervous system.
This proposal envisions six main objectives to significantly advance development of an auto-injectable
diazepam as a first-line, at-home treatment for uncontrolled seizures.
1. Optimize XeriSol™ non-aqueous, soluble, stable diazepam formulations to provide the desired
pharmacokinetic (PK) profile and confirm container-closure compatibility.
2. Manufacture at least three (3) GLP batches of non-clinical supplies of the optimized formulations and place
these supplies on a short term stability study (real-time and accelerated).
3. Conduct IND-enabling animal studies:
a. A 14-day safety-tolerability study in rats evaluating three (3) XeriSol diazepam formulations by daily
subcutaneous and intradermal routes of injection.
b. A comparative GLP PK study in mini pigs with Xeris’ non-aqueous diazepam and DiaStat®. This study
will seek to demonstrate pharmacological comparability between the two products administered via
intradermal and subcutaneous injection with respect to tolerability various PK parameters including Cmax,
Tmax, and AUC compared to DiaStat® rectal gel.
4. Manufacture two (2) cGMP clinical batches of the drug product formulation in vials for the first clinical trial
and place this batch on an ICH-compliant long-term stability study.
5. Conduct a comprehensive risk analysis and formative comparative human factors study with a DiazePen™
auto-injector and the commercial rectal gel applicator (Diastat® AcuDial).
6. Prepare and submit an amended IND application to the FDA seeking clearance for a Phase 1 clinical study.
在此快速通道应用程序中概述的程序旨在加速开发,
DiazePen™用于治疗癫痫患者不受控制的癫痫发作的商业化。的
设想的产品将用一种新的药物替代目前的护理标准,地西泮直肠凝胶(DiaStat®),
用于通过皮下注射快速递送的制剂。为此,Xeris将使用其专有配方
平台(XeriSol™),该平台已经证明了非常低体积的稳定地西泮的可行性,
与DiaStat®相似的药代动力学。这些目标的顺利完成将推动
DiazePen™通过处方优化和非临床阶段,IND申请和生产
为Xeris Pharmaceuticals申办的未来1期临床试验提供临床用品。本研究
与NINDS直接相关,NINDS明确对开发创新疗法感兴趣,
神经系统疾病,包括用于治疗神经系统疾病的治疗剂(药物、生物制剂和/或器械)
疾病和向中枢神经系统递送治疗剂的技术/方法。
该提案设想了六个主要目标,以显着推进自动注射的发展
地西泮作为治疗不受控制的癫痫发作的一线家庭治疗方法。
1.优化XeriSol™非水、可溶、稳定的地西泮制剂,以提供所需的
药代动力学(PK)特征,并确认容器-密封件相容性。
2.生产至少三(3)批优化制剂的非临床供应品的GLP批次,并放置
对这些供应品进行短期稳定性研究(实时和加速)。
3.进行IND启用动物研究:
a.大鼠14天安全性-耐受性研究,每日评价3种XeriSol地西泮制剂
皮下和皮内注射途径。
B. Xeris非水性地西泮和DiaStat®在小型猪中的GLP PK比较研究。本研究
将寻求证明两种产品之间的药理学可比性,
皮内和皮下注射对于耐受性的各种PK参数,
Tmax和AUC。
4.生产两(2)个cGMP临床批次的小瓶制剂制剂,用于首次临床试验
并将该批次进行ICH合规性长期稳定性研究。
5.使用DiazePen™进行全面的风险分析和形成性比较人为因素研究
自动注射器和市售直肠凝胶施用器(Diastat® AcuDial)。
6.准备并向FDA提交修正的IND申请,以寻求1期临床研究的批准。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES C. CLOYD其他文献
JAMES C. CLOYD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES C. CLOYD', 18)}}的其他基金
Auto-Injectable Diazepam Formulation for Rapid Treatment of Uncontrolled Seizures
用于快速治疗失控癫痫发作的自动注射地西泮制剂
- 批准号:
9049665 - 财政年份:2015
- 资助金额:
$ 79.72万 - 项目类别:
Indo-US Research Conference on Rare Diseases and Orphan Drugs
印度-美国罕见病和孤儿药研究会议
- 批准号:
7913965 - 财政年份:2010
- 资助金额:
$ 79.72万 - 项目类别:
PHARMACOKINETICS AND SAFETY OF INTRAVENOUS TOPIRAMATE IN ADULT PATIENTS
成人患者静脉注射托吡酯的药代动力学和安全性
- 批准号:
7951634 - 财政年份:2008
- 资助金额:
$ 79.72万 - 项目类别:
Phase I Study in Patients Supporting IV TPM for Neonatal Seizures (9/07, IND7899)
支持 IV TPM 治疗新生儿癫痫患者的 I 期研究(9/07,IND7899)
- 批准号:
7936708 - 财政年份:2008
- 资助金额:
$ 79.72万 - 项目类别:
Phase I Study in Patients Supporting IV TPM for Neonatal Seizures (9/07, IND7899)
支持 IV TPM 治疗新生儿癫痫患者的 I 期研究(9/07,IND7899)
- 批准号:
7564660 - 财政年份:2008
- 资助金额:
$ 79.72万 - 项目类别:
PHARMACOKINETICS AND METABOLISM OF ANTIEPILEPTIC DRUGS IN ELDERLY PATIENTS
老年患者抗癫痫药物的药代动力学和代谢
- 批准号:
7605957 - 财政年份:2006
- 资助金额:
$ 79.72万 - 项目类别:
PHARMACOKINETICS AND METABOLISM OF ANTIEPILEPTIC DRUGS IN ELDERLY PATIENTS
老年患者抗癫痫药物的药代动力学和代谢
- 批准号:
7375860 - 财政年份:2005
- 资助金额:
$ 79.72万 - 项目类别:
Effects of age, gender and race on antiepileptic drugs
年龄、性别和种族对抗癫痫药物的影响
- 批准号:
7119178 - 财政年份:2005
- 资助金额:
$ 79.72万 - 项目类别:
PHARMACOKINETICS AND METABOLISM OF ANTIEPILEPTIC DRUGS IN ELDERLY PATIENTS
老年患者抗癫痫药物的药代动力学和代谢
- 批准号:
7206428 - 财政年份:2005
- 资助金额:
$ 79.72万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 79.72万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 79.72万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 79.72万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 79.72万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 79.72万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 79.72万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 79.72万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 79.72万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 79.72万 - 项目类别: